Top

Published in:

01-08-2018 | Original Article

Comparative clinicopathological and cytomorphological analyses of peritoneal carcinomatosis associated with metastatic breast carcinoma and primary peritoneal/ovarian carcinoma in patients with a history of breast carcinoma

Authors: Kiyong Na, Jung-Yun Lee, Ji-Youn Sung, Gun Min Kim, Ja Seung Koo, Hyun-Soo Kim

Published in: Virchows Archiv | Issue 2/2018

Abstract

Causes of peritoneal carcinomatosis (PC) in patients with a history of breast carcinoma include both metastatic breast carcinoma (MBC) and primary peritoneal/ovarian carcinoma (PPOC). The origin of PC is important to determine the appropriate treatment strategy. Cytological examination of the peritoneal fluid (PF), which may be the first diagnostic approach to PC, is of distinct value in confirming the presence of malignant cells and determining the origin of PC. We analyzed the clinicopathological and cytomorphological characteristics of 33 patients with a history of breast carcinoma whose PF cytology contained malignant cells. Cases showing positive immunoreactivity for PAX8 and a lack of GATA3 expression were considered as PPOC. Sixteen patients developed PC caused by PPOC. PPOC patients were characterized by early-stage primary breast carcinoma, absence of non-peritoneal MBC before PC, and normal serum levels of CEA and CA15-3. Fourteen PPOC patients had pathogenic germline BRCA mutations. Cytological examination revealed that most of the PPOC cases had a dominant papillary arrangement of the tumor cells with severe nuclear pleomorphism, occasional bizarre nuclei, and atypical mitotic figures. Patients with PPOC who underwent cytoreductive surgery had a significantly longer survival time compared to those who did not, or MBC patients. In patients with a history of breast carcinoma presenting with PC, the presence of early-stage primary breast carcinoma, no prior non-peritoneal MBC, and a dominant papillary cellular arrangement pattern in the PF cytology were independent predictors of PPOC. Cytoreductive surgery significantly improved survival for patients with PPOC.

Available only for authorised users

Kim YA, Oh IH, Yoon SJ, Kim HJ, Seo HY, Kim EJ, Lee YH, Jung JH (2015) The economic burden of breast cancer in Korea from 2007-2010. Cancer Res Treat 47:583–590. https://doi.org/10.4143/crt.2014.143 CrossRefPubMedPubMedCentral

Bouganim N, Tsvetkova E, Clemons M, Amir E (2013) Evolution of sites of recurrence after early breast cancer over the last 20 years: implications for patient care and future research. Breast Cancer Res Treat 139:603–606. https://doi.org/10.1007/s10549-013-2561-7 CrossRefPubMed

Bertozzi S, Londero AP, Cedolini C, Uzzau A, Seriau L, Bernardi S, Bacchetti S, Pasqual EM, Risaliti A (2015) Prevalence, risk factors, and prognosis of peritoneal metastasis from breast cancer. Springerplus 4:688. https://doi.org/10.1186/s40064-015-1449-x CrossRefPubMedPubMedCentral

Sheen-Chen SM, Liu YW, Sun CK, Lin SE, Eng HL, Huang WT, Ko SF (2008) Abdominal carcinomatosis attributed to metastatic breast carcinoma. Dig Dis Sci 53:3043–3045. https://doi.org/10.1007/s10620-008-0529-y CrossRefPubMed

Jung HK, Park S, Kim NW, Lee JE, Kim Z, Han SW, Hur SM, Kim SY, Lim CW, Lee MH, Lee J (2017) Development of second primary cancer in Korean breast cancer survivors. Ann Surg Treat Res 93:287–292. https://doi.org/10.4174/astr.2017.93.6.287 CrossRefPubMedPubMedCentral

Curtin JP, Barakat RR, Hoskins WJ (1994) Ovarian disease in women with breast cancer. Obstet Gynecol 84:449–452PubMed

Garg R, Zahurak ML, Trimble EL, Armstrong DK, Bristow RE (2005) Abdominal carcinomatosis in women with a history of breast cancer. Gynecol Oncol 99:65–70. https://doi.org/10.1016/j.ygyno.2005.05.013 CrossRefPubMed

Pereira TC, Saad RS, Liu Y, Silverman JF (2006) The diagnosis of malignancy in effusion cytology: a pattern recognition approach. Adv Anat Pathol 13:174–184CrossRefPubMed

Bedrossian CW (1998) Special stains, the old and the new: the impact of immunocytochemistry in effusion cytology. Diagn Cytopathol 18:141–149CrossRefPubMed

10.

Nance KV, Silverman JF (1992) The utility of ancillary techniques in effusion cytology. Diagn Cytopathol 8:185–189CrossRefPubMed

11.

Shield PW, Papadimos DJ, Walsh MD (2014) GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens. Cancer Cytopathol 122:307–312. https://doi.org/10.1002/cncy.21393 CrossRefPubMed

12.

Wang Y, Wang Y, Li J, Yuan Z, Yuan B, Zhang T, Cragun JM, Kong B, Zheng W (2013) PAX8: a sensitive and specific marker to identify cancer cells of ovarian origin for patients prior to neoadjuvant chemotherapy. J Hematol Oncol 6:60. https://doi.org/10.1186/1756-8722-6-60 CrossRefPubMedPubMedCentral

13.

Lee BH, Hecht JL, Pinkus JL, Pinkus GS (2002) WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids. Am J Clin Pathol 117:745–750. https://doi.org/10.1309/QLV6-HH0H-UCTF-WEF6 CrossRefPubMed

14.

Waters L, Crumley S, Truong L, Mody D, Coffey D (2014) PAX2 and PAX8: useful markers for metastatic effusions. Acta Cytol 58:60–66. https://doi.org/10.1159/000356426 CrossRefPubMed

15.

Na K, Kim HS (2017) Clinicopathological characteristics of fallopian tube metastases from primary endometrial, cervical, and nongynecological malignancies: a single institutional experience. Virchows Arch 471:363–373. https://doi.org/10.1007/s00428-017-2186-z CrossRefPubMed

16.

Na K, Kim HS (2017) Clinicopathologic and molecular characteristics of mesonephric adenocarcinoma arising from the uterine body. Am J Surg Pathol:1. https://doi.org/10.1097/PAS.0000000000000991

17.

Na K, Sung JY, Kim HS (2017) TP53 mutation status of tubo-ovarian and peritoneal high-grade serous carcinoma with a wild-type p53 immunostaining pattern. Anticancer Res 37:6697–6703. https://doi.org/10.21873/anticanres.12128 PubMedCrossRef

18.

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795. https://doi.org/10.1200/JCO.2009.25.6529 CrossRefPubMedPubMedCentral

19.

Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997–4013. https://doi.org/10.1200/JCO.2013.50.9984 CrossRefPubMed

20.

Tuthill M, Pell R, Guiliani R, Lim A, Gudi M, Contractor KB, Lewis JS, Coombes RC, Stebbing J (2009) Peritoneal disease in breast cancer: a specific entity with an extremely poor prognosis. Eur J Cancer 45:2146–2149. https://doi.org/10.1016/j.ejca.2009.04.027 CrossRefPubMed

21.

Ingham SL, Warwick J, Buchan I, Sahin S, O'Hara C, Moran A, Howell A, Evans DG (2013) Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2. J Med Genet 50:368–372. https://doi.org/10.1136/jmedgenet-2013-101607 CrossRefPubMed

22.

Gulhan I, Eser S, Yakut C, Bige O, Ilhan E, Yildirim Y, Saygili U (2009) Second primary gynecologic cancers after breast cancer in Turkish women. Int J Gynecol Cancer 19:648–650. https://doi.org/10.1111/IGC.0b013e3181a12e8b CrossRefPubMed

23.

Trentham-Dietz A, Newcomb PA, Nichols HB, Hampton JM (2007) Breast cancer risk factors and second primary malignancies among women with breast cancer. Breast Cancer Res Treat 105:195–207. https://doi.org/10.1007/s10549-006-9446-y CrossRefPubMed

24.

Kehl KL, Shen C, Litton JK, Arun B, Giordano SH (2016) Rates of BRCA1/2 mutation testing among young survivors of breast cancer. Breast Cancer Res Treat 155:165–173. https://doi.org/10.1007/s10549-015-3658-y CrossRefPubMed

25.

Manchanda R, Legood R, Burnell M, McGuire A, Raikou M, Loggenberg K, Wardle J, Sanderson S, Gessler S, Side L, Balogun N, Desai R, Kumar A, Dorkins H, Wallis Y, Chapman C, Taylor R, Jacobs C, Tomlinson I, Beller U, Menon U, Jacobs I (2015) Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing. J Natl Cancer Inst 107:380. https://doi.org/10.1093/jnci/dju380 PubMedCrossRef

26.

Tserkezoglou A, Kontou S, Hadjieleftheriou G, Apostolikas N, Vassilomanolakis M, Sikiotis K, Salamalekis E, Tseke P, Magiakos G (2006) Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results. Anticancer Res 26:2339–2344PubMed

27.

Kumar P, Aggarwal R (2016) An overview of triple-negative breast cancer. Arch Gynecol Obstet 293:247–269. https://doi.org/10.1007/s00404-015-3859-y CrossRefPubMed

28.

Hudis CA, Gianni L (2011) Triple-negative breast cancer: an unmet medical need. Oncologist 16(Suppl 1):1–11. https://doi.org/10.1634/theoncologist.2011-S1-01 CrossRefPubMed

29.

Meyer P, Landgraf K, Hogel B, Eiermann W, Ataseven B (2012) BRCA2 mutations and triple-negative breast cancer. PLoS One 7:e38361. https://doi.org/10.1371/journal.pone.0038361 CrossRefPubMedPubMedCentral

30.

Hahnen E, Hauke J, Engel C, Neidhardt G, Rhiem K, Schmutzler RK (2017) Germline mutations in triple-negative breast cancer. Breast Care (Basel) 12:15–19. https://doi.org/10.1159/000455999 CrossRef

31.

Zhang M, Sun J (2013) Bone metastasis from ovarian cancer. Clinical analysis of 26 cases. Saudi Med J 34:1270–1273PubMed

32.

Cormio G, Capotorto M, Di Vagno G, Cazzolla A, Carriero C, Selvaggi L (2003) Skin metastases in ovarian carcinoma: a report of nine cases and a review of the literature. Gynecol Oncol 90:682–685CrossRefPubMed

33.

Li Q, Xu BH, Zhang P, Li Q, Yuan P, Wang JY, Luo Y, Ma F, Fan Y, Li Q (2013) Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases. Zhonghua Zhong Liu Za Zhi 35:207–211. https://doi.org/10.3760/cma.j.issn.0253-3766.2013.03.010 PubMedCrossRef

34.

Raptis S, Kanbour AI, Dusenbery D, Kanbour-Shakir A (1996) Fine-needle aspiration cytology of metastatic ovarian carcinoma to the breast. Diagn Cytopathol 15:1–6. https://doi.org/10.1002/(SICI)1097-0339(199607)15:1<1::AID-DC2>3.0.CO;2-N CrossRefPubMed

35.

Bayramoglu H, Zekioglu O, Erhan Y, Ciris M, Ozdemir N (2002) Fine-needle aspiration biopsy of invasive micropapillary carcinoma of the breast: a report of five cases. Diagn Cytopathol 27:214–217. https://doi.org/10.1002/dc.10176 CrossRefPubMed

36.

Jaffer S, Reid-Nicholson M, Bleiweiss IJ (2002) Infiltrating micropapillary carcinoma of the breast. Cytologic Findings Acta Cytol 46:1081–1087. https://doi.org/10.1159/000327111 CrossRefPubMed

37.

Gown AM, Fulton RS, Kandalaft PL (2016) Markers of metastatic carcinoma of breast origin. Histopathology 68:86–95. https://doi.org/10.1111/his.12877 CrossRefPubMed

38.

Sheikh UN, Cohen C, Siddiqui MT (2016) Utility of folate receptor alpha immunohistochemistry in cytology specimens of metastatic breast carcinoma, metastatic serous carcinoma of Mullerian origin, and primary lung adenocarcinoma. Diagn Cytopathol 44:369–376. https://doi.org/10.1002/dc.23448 CrossRefPubMed

39.

Rossi S, Basso M, Strippoli A, Dadduzio V, Cerchiaro E, Barile R, D'Argento E, Cassano A, Schinzari G, Barone C (2015) Hormone receptor status and HER2 expression in primary breast cancer compared with synchronous axillary metastases or recurrent metastatic disease. Clin Breast Cancer 15:307–312. https://doi.org/10.1016/j.clbc.2015.03.010 CrossRefPubMed

40.

Nakayama Y, Nakagomi H, Omori M, Inoue M, Takahashi K, Maruyama M, Takano A, Furuya K, Amemiya K, Ishii E, Oyama T (2016) Benefits of using the cell block method to determine the discordance of the HR/HER2 expression in patients with metastatic breast cancer. Breast Cancer 23:633–639. https://doi.org/10.1007/s12282-015-0615-x CrossRefPubMed

Title: Comparative clinicopathological and cytomorphological analyses of peritoneal carcinomatosis associated with metastatic breast carcinoma and primary peritoneal/ovarian carcinoma in patients with a history of breast carcinoma
Authors: Kiyong Na
Jung-Yun Lee
Ji-Youn Sung
Gun Min Kim
Ja Seung Koo
Hyun-Soo Kim
Publication date: 01-08-2018
Publisher: Springer Berlin Heidelberg
Published in: Virchows Archiv / Issue 2/2018
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-018-2390-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Comparative clinicopathological and cytomorphological analyses of peritoneal carcinomatosis associated with metastatic breast carcinoma and primary peritoneal/ovarian carcinoma in patients with a history of breast carcinoma

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2018

The impact of complete embedding of remaining tissue in gynecological lymph node dissection specimen in surgical pathology on lymph node yield: is it clinically relevant?

Interobserver variability in the H&E-based assessment of tumor budding in pT3/4 colon cancer: does it affect the prognostic relevance?

HOXB13 is not expressed in pleomorphic giant cell carcinoma of the bladder

Reply to the letter “How to standardize the evaluation of tumor regression grading of gastrointestinal cancers after neoadjuvant therapy?” by Dr. Nasierowska-Guttmejer and Dr. Szawlowski, VIAR-D-18-00181

Genetic zygosity of mature ovarian teratomas, struma ovarii, and ovarian carcinoids

Analysis of membranous Ki-67 staining in breast cancer and surrounding breast epithelium